Amphion Innovations PLC Additional Draw Down on Loan Facility (8230H)
August 22 2016 - 10:58AM
UK Regulatory
TIDMAMP
RNS Number : 8230H
Amphion Innovations PLC
22 August 2016
Amphion Innovations plc
("Amphion" or "the Company")
Additional Draw Down on Loan Facility
London and New York, 22 August 2016 - Amphion Innovations plc
(AIM: AMP), the developer of medical, life science, and technology
businesses, today announces that the Company has agreed terms for
the draw-down of an additional tranche of US $2,350,000 (an
"Additional Draw") under the loan facility as announced on 5 June
2014 (the "Facility").
Under the terms of the Additional Draw, the interest rate will
be 10% with repayments starting on 1 January 2017 and with the
final repayment due on 1 December 2017. The proceeds are to be used
to repay the existing amount due under the Facility and for working
capital for Amphion and its Partner Companies.
The loan is secured by the pledge by the Company of 8,754,255
ordinary shares of Kromek Group plc and 27,961,625 ordinary shares
of Motif Bio plc.
The current loan balance under the Facility after the Additional
Draw will be US $6,198,333. Of this amount, US $3,000,000, plus
interest is convertible into the ordinary shares of Amphion
Innovations plc at 6 pence and the remaining amount, plus interest
is convertible at 8 pence.
Richard Morgan, CEO of Amphion, said: "We continue to believe in
the future upside potential of our holdings in our Partner
Companies. We are working on moving other programmes forward and
this facility gives us access to additional working capital to help
develop the emerging companies and to progress the pipeline."
For further information please contact:
Amphion Innovations
Charlie Morgan
+1 212 210 6224
Yellow Jersey PR
Charles Goodwin / Dominic Barretto
+44 (0)7747 788 221
Panmure Gordon Limited (Nominated Adviser and Corporate
Broker)
Freddy Crossley / Duncan Monteith (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500
Northland Capital Partners Limited (Joint Corporate Broker)
Patrick Claridge / David Hignell (Corporate Finance)
John Howes (Corporate Broking)
+44 (0)20 7382 1100
Plumtree Capital Limited (Financial Adviser)
Stephen Austin
+44 (0)20 7183 2493
+646 568 7502
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and
technology businesses.
We use our extensive experience in company building to invest
and build shareholder value in high growth companies in the US and
UK. Amphion has significant shareholding in 7 Partner Companies
developing proven technologies targeting substantial commercial
marketplaces. The Amphion model has been refined to optimise the
commercialisation of patents and other intellectual property within
the Partner Companies. The Partner Companies collectively own or
control over 200 separately identified pieces of intellectual
property, a number which grows rapidly each year.
On the web: www.amphionplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBSGDIUUDBGLD
(END) Dow Jones Newswires
August 22, 2016 10:58 ET (14:58 GMT)
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Apr 2023 to Apr 2024